Your browser is no longer supported. Please, upgrade your browser.
ARNA Arena Pharmaceuticals, Inc. daily Stock Chart
ARNA [NASD]
Arena Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-6.46 Insider Own0.20% Shs Outstand56.66M Perf Week4.47%
Market Cap3.70B Forward P/E- EPS next Y-8.18 Insider Trans-69.71% Shs Float50.26M Perf Month2.04%
Income-322.80M PEG- EPS next Q-2.06 Inst Own80.20% Short Float7.78% Perf Quarter39.37%
Sales5.60M P/S659.91 EPS this Y-210.90% Inst Trans7.65% Short Ratio5.03 Perf Half Y42.47%
Book/sh19.68 P/B3.35 EPS next Y4.10% ROA-27.00% Target Price77.82 Perf Year8.49%
Cash/sh14.27 P/C4.62 EPS next 5Y- ROE-29.30% 52W Range32.95 - 69.75 Perf YTD45.13%
Dividend- P/FCF- EPS past 5Y36.80% ROI33.20% 52W High-5.49% Beta1.46
Dividend %- Quick Ratio18.70 Sales past 5Y85.20% Gross Margin- 52W Low100.06% ATR2.90
Employees320 Current Ratio18.70 Sales Q/Q-100.00% Oper. Margin- RSI (14)59.89 Volatility3.35% 4.38%
OptionableYes Debt/Eq0.05 EPS Q/Q-116.50% Profit Margin- Rel Volume0.35 Prev Close65.75
ShortableYes LT Debt/Eq0.05 EarningsMay 07 AMC Payout- Avg Volume777.44K Price65.92
Recom1.60 SMA203.26% SMA5011.97% SMA20032.46% Volume272,501 Change0.26%
Jun-29-20Initiated H.C. Wainwright Buy $90
May-18-20Initiated Jefferies Buy $62
Mar-31-20Initiated Guggenheim Buy $95
Mar-26-20Upgrade BofA/Merrill Neutral → Buy $47 → $56
Jan-31-20Upgrade JP Morgan Neutral → Overweight $58
Nov-13-19Initiated BofA/Merrill Neutral $51
Dec-13-18Initiated Berenberg Buy $55
May-31-18Initiated RBC Capital Mkts Outperform $65
Mar-21-18Upgrade Needham Hold → Buy $60
Mar-20-18Reiterated JMP Securities Mkt Outperform $63 → $79
Jan-18-18Resumed Credit Suisse Outperform $44
Jan-18-18Initiated Credit Suisse Outperform $44
Jan-03-18Upgrade Wells Fargo Market Perform → Outperform
Jul-11-17Reiterated Citigroup Buy $23 → $37
Jul-07-17Upgrade JMP Securities Mkt Perform → Mkt Outperform
Jun-27-17Initiated Citigroup Buy $23
May-19-17Initiated Leerink Partners Outperform $5
Sep-15-16Initiated FBR & Co. Outperform $6
Mar-01-16Reiterated RBC Capital Mkts Sector Perform $2 → $1.50
Nov-11-15Reiterated RBC Capital Mkts Sector Perform $5 → $2
Jun-18-20 04:01PM  
Jun-15-20 08:30AM  
Jun-08-20 04:30PM  
01:28PM  
Jun-03-20 01:13AM  
Jun-02-20 04:23PM  
Jun-01-20 04:01PM  
09:30AM  
May-28-20 08:30AM  
May-27-20 04:01PM  
May-26-20 08:30AM  
May-22-20 04:30PM  
May-20-20 04:01PM  
May-19-20 04:10PM  
May-13-20 04:01PM  
09:18AM  
May-10-20 08:18AM  
May-08-20 03:01PM  
10:39AM  
May-07-20 04:01PM  
May-06-20 08:30AM  
Apr-30-20 08:30AM  
Apr-24-20 09:00AM  
Apr-19-20 08:27AM  
Apr-14-20 01:47PM  
Apr-10-20 01:09PM  
Apr-07-20 08:05PM  
Apr-01-20 04:01PM  
Mar-30-20 08:30AM  
Mar-18-20 04:01PM  
02:29PM  
Mar-09-20 01:30PM  
10:18AM  
Feb-28-20 05:38AM  
Feb-27-20 01:48PM  
10:40AM  
Feb-26-20 04:01PM  
09:36AM  
Feb-21-20 04:11PM  
Feb-20-20 08:30AM  
Feb-19-20 04:06PM  
Feb-13-20 06:09AM  
Feb-11-20 03:06PM  
Jan-31-20 03:45PM  
Jan-17-20 08:16AM  
Jan-16-20 09:00AM  
Jan-13-20 04:01PM  
Jan-08-20 09:27AM  
08:30AM  
Jan-07-20 07:57AM  
Jan-06-20 04:01PM  
Jan-03-20 09:01AM  
Jan-02-20 08:30AM  
Dec-30-19 08:52AM  
Dec-19-19 02:32PM  
Dec-13-19 02:31PM  
Dec-03-19 04:35PM  
Nov-27-19 06:34PM  
Nov-26-19 08:30AM  
Nov-18-19 04:01PM  
Nov-14-19 09:00AM  
Nov-10-19 07:43AM  
Nov-08-19 08:56AM  
Nov-07-19 04:01PM  
Nov-06-19 08:30AM  
Nov-05-19 05:41PM  
Oct-31-19 11:45AM  
08:30AM  
Oct-28-19 08:30AM  
Oct-23-19 01:26PM  
Oct-22-19 04:01PM  
Oct-18-19 03:01AM  
Oct-05-19 09:51AM  
Sep-26-19 08:30AM  
Sep-25-19 08:30AM  
Sep-17-19 08:30AM  
Sep-12-19 11:25AM  
Sep-10-19 11:15PM  
Sep-09-19 08:30AM  
Sep-05-19 11:23AM  
Aug-28-19 08:30AM  
Aug-13-19 12:44PM  
Aug-08-19 04:47PM  
04:08PM  
10:34AM  
04:23AM  
Aug-07-19 04:01PM  
Aug-06-19 03:50PM  
Aug-01-19 09:49AM  
Jul-31-19 08:30AM  
Jul-29-19 10:34AM  
Jul-25-19 09:00AM  
08:30AM  
Jul-09-19 01:32PM  
Jun-18-19 12:30PM  
10:38AM  
Jun-17-19 08:30AM  
Jun-14-19 06:29PM  
Jun-13-19 06:29PM  
08:30AM  
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include ralinepag (APD811), which is in Phase III trial to treat pulmonary arterial hypertension; etrasimod (APD334) for ulcerative colitis, and Crohn's disease, as well as for atopic dermatitis and other indications; and Olorinab (APD371), which is in Phase II trial for the treatment of gastrointestinal pain. It is also developing APD418, a calcium-independent myofilament derepressor for the treatment of decompensated heart failure. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Axovant Sciences GmbH; Outpost Medicine LLC; CY Biotech Company Limited; Boehringer Ingelheim International GmbH; Eisai Co., Ltd.; and Eisai Inc. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Soni Manmeet SinghDirectorJun 17Sale62.7430419,0735,902Jun 18 05:07 PM
Soni Manmeet SinghDirectorJun 15Sale60.121,32779,7796,206Jun 16 08:54 PM
Munshi AmitPresident and CEOJun 03Option Exercise15.3550,000767,67557,750Jun 04 06:34 PM
Munshi AmitPresident and CEOJun 03Sale68.5450,0003,427,2367,750Jun 04 06:34 PM
Aurentz VincentExecutive VP and CBOJun 02Option Exercise19.8025,000495,00025,000Jun 04 06:40 PM
Munshi AmitPresident and CEOJun 02Option Exercise14.6050,000730,00057,750Jun 04 06:34 PM
Munshi AmitPresident and CEOJun 02Sale65.0050,0003,250,0007,750Jun 04 06:34 PM
Aurentz VincentExecutive VP and CBOJun 02Sale65.0025,0001,625,0230Jun 04 06:40 PM
Munshi AmitPresident and CEOMay 22Option Exercise14.6034,800508,08042,550May 22 07:31 PM
Munshi AmitPresident and CEOMay 22Sale58.1234,8002,022,6087,750May 22 07:31 PM
Munshi AmitPresident and CEOMay 21Option Exercise14.6050,000730,00057,750May 22 07:31 PM
Munshi AmitPresident and CEOMay 21Sale55.0050,0002,750,0007,750May 22 07:31 PM
SPECTOR STEVEN WEVP, General Counsel & SecFeb 27Option Exercise14.907,970118,75317,437Feb 28 06:02 PM
SPECTOR STEVEN WEVP, General Counsel & SecFeb 13Option Exercise35.647,436265,00120,303Feb 14 07:43 PM
Munshi AmitPresident and CEOFeb 13Option Exercise14.6015,200221,92022,950Feb 14 07:37 PM
Lind Kevin RobertExecutive VP and CFOFeb 13Option Exercise26.604,500119,7007,957Feb 14 07:40 PM
Munshi AmitPresident and CEOFeb 13Sale55.0015,200836,0007,750Feb 14 07:37 PM
SPECTOR STEVEN WEVP, General Counsel & SecFeb 13Sale55.0010,836595,9809,467Feb 14 07:43 PM
Lind Kevin RobertExecutive VP and CFOFeb 13Sale55.004,500247,5003,457Feb 14 07:40 PM
Aurentz VincentExecutive VP and CBOFeb 05Sale50.009,000450,0000Feb 07 04:34 PM
Munshi AmitPresident and CEOFeb 05Sale50.007,129356,4507,750Feb 07 04:31 PM
Lisicki RobertEVP, Chief Commercial OfficerNov 13Sale45.834,429203,0000Nov 26 05:44 PM
WOODS RANDALL EDirectorNov 12Option Exercise32.503,04698,99517,276Nov 13 08:14 PM
WOODS RANDALL EDirectorNov 12Sale46.733,046142,34014,230Nov 13 08:14 PM
SPECTOR STEVEN WEVP, General Counsel & SecOct 14Option Exercise0.006,300015,990Oct 16 08:22 PM
Lisicki RobertEVP, Chief Commercial OfficerOct 14Option Exercise0.006,30006,300Oct 16 08:21 PM
Klassen PrestonEVP and CMOOct 14Option Exercise0.006,30006,300Oct 16 08:20 PM
Aurentz VincentExecutive VP and CBOOct 14Option Exercise0.009,00009,000Oct 16 08:19 PM
Lind Kevin RobertExecutive VP and CFOOct 14Option Exercise0.006,30006,548Oct 16 08:18 PM
Munshi AmitPresident and CEOOct 14Option Exercise0.0011,700019,450Oct 16 08:17 PM
SPECTOR STEVEN WEVP, General Counsel & SecSep 10Option Exercise15.5012,627195,71922,317Sep 10 09:03 PM
SPECTOR STEVEN WEVP, General Counsel & SecSep 10Sale50.2812,627634,8739,690Sep 10 09:03 PM
SPECTOR STEVEN WEVP, General Counsel & SecSep 09Option Exercise18.7421,457402,18641,147Sep 10 09:03 PM
Aurentz VincentExecutive VP and CBOSep 09Option Exercise25.2565,0001,641,50065,000Sep 10 09:05 PM
Aurentz VincentExecutive VP and CBOSep 09Sale50.7265,0003,296,7000Sep 10 09:05 PM
SPECTOR STEVEN WEVP, General Counsel & SecSep 09Sale50.7231,4571,595,5159,690Sep 10 09:03 PM